When: No breakout within 5-7 sessions

Then: Reset trigger to 144-146 retest

HOLD with trim-on-strength instruction; stop at 147.50; no-add rule at 150; specifically opposed to adding at 147-148

• September 18 volume of 16.34 million shares at resistance (152-154) resulted in rejection close at 150.11, defined as supply response rather than institutional accumulation
• Balance sheet deteriorated sharply: D/E jumped to 2.22x, net debt surged from 14.55B to 23.07B in one quarter, stockholders' equity cut in half, current ratio fell from 1.97 to 1.27, working capital dropped 6.24B
• Trailing free cash flow of 9.77B is strong but must now service a larger debt load while funding dividends, buybacks, and Q2 acquisition integration costs
• MACD rolled over from peak of 4.43 in late August to 2.60 with bearish cross confirmed; RSI pulled back from 74 to 62.59; all three momentum measures rolling over at resistance simultaneously
• Risk-reward unfavorable for adding: 6-8% downside risk to 50 SMA at 138.85 versus only 4-7% upside to 158 resistance; 2.17% dividend does not offset a 7% drawdown
• Valuation stretched: forward P/E of 15x on normalized EPS of 9.89, but PEG is 2.2 and price-to-book is 15.75x with tangible book now negative due to intangibles dominance
• Q3 Yeztugo disclosure is a binary catalyst with downside scenarios including cautious Lenacapavir guidance, HIV base softness, or further integration costs from Q2 acquisition

→ vs aggressive: Volume of 16.34M shares on September 18 was a supply response (price tagged 153.23 upper Bollinger Band, closed at 150.11 near lows of day on double average volume), not institutional accumulation; aggressive analyst is pre-committing capital to a resolution that hasn't happened yet

→ vs aggressive: D/E of 2.22x, net debt at 23.07B, current ratio at 1.27, and working capital down 6.24B represent materially higher leverage and thinner liquidity regardless of non-cash impairment accounting; equity impairment already happened and signals aggressive initial underwriting assumptions

→ vs aggressive: MACD cross at 2.60 versus 2.80 cannot be dismissed as just a momentum reset when combined with price rejection at upper Bollinger Band and RSI rolling over from 74 to 62.59; multiple indicators agreeing on warning requires respect

→ vs aggressive: Risk-reward math is the same regardless of holding period: 6-8% downside versus 4-7% upside does not improve with dividend; 2.17% annualized yield cannot offset a 7% drawdown in three months or a 10% drawback scenario

→ vs aggressive: PEG of 2.2 and price-to-book of 15.75x with tangible book negative indicates thin margin of safety; in 5% 10-year yield environment with 95% probability of no 2026 Fed cuts, the multiple has a ceiling and adding at current levels is adding at the ceiling

→ vs aggressive: Q3 Yeztugo catalyst is binary in both directions; aggressive analyst prices only the good resolution while conservative position prices revenue disappointment, cautious Lenacapavir guidance, HIV base softness, and further integration costs as equally likely outcomes

HOLD with no-add at current 150 level; trim 10% only on second consecutive rejection at 154 with declining volume; add on breakout above 151.68 on volume above 10 million with MACD turning bullish, or on pullback to 138 to 143 zone with 50 SMA holding and MACD resetting toward neutral; stop at 147.50

• 16.34 million shares with tag at 153.23 and close at 150.11 represents unresolved supply response, not confirmed bullish digestion or definitive top
• Current ratio of 1.27 at 9.77 billion trailing free cash flow with full capital markets access is not a liquidity crisis; leverage is real but company not cornered
• 11.2 billion acquisition impairment reflects aggressive initial underwriting, a data point on M&A discipline, not just an accounting line
• Three momentum measures aligning on caution: MACD rolling from 4.43 to positive 2.60 versus 2.80, RSI from 74 to 62, and Bollinger Band rejection at same resistance level
• 50 SMA at 138.85 represents 7% drop and first real technical support; healthy pullback to that zone is trend behavior, not regime change
• Risk-reward of 1 to 3.7 is unfavorable at 147 to 148 specifically but becomes attractive at 138 to 143 pullback zone
• Normalized EPS of 9.89 with 15x forward P/E appears reasonable but PEG at 2.2 and P/B at 15.75 with negative tangible book indicate market is paying premium for stability and yield
• Higher-for-longer rate regime with 10-year near 5 percent and 95 percent probability priced for no 2026 Fed cuts is a multiple headwind that caps near-term upside
• Q3 earnings are early November, 6 to 7 weeks away, which disciplines position sizing rather than driving it
• 2.17 percent dividend provides cushion but does not offset 7 percent drawdown risk or justify new risk at current levels
• Stop level of 147.50 is just below the 10 EMA and recent swing low
• Breakout add criteria: confirmed close above 151.68 on volume above 10 million with MACD turning bullish; pullback add criteria: 138 to 143 zone with 50 SMA holding and MACD resetting toward neutral with stop below 133.67

→ vs aggressive: Calling 16.34 million shares at resistance 'bullish digestion' requires deciding institutional intent in advance; that's narrative fitting, not analysis

→ vs aggressive: Adding at 147 to 148 means increasing exposure right as the next directional move is being decided, when capital efficiency is worst

→ vs aggressive: Framing this as a 'buying opportunity' at resistance is thinking that works in strong trends but fails at regime-change moments

→ vs aggressive: Thesis requires multiple expansion to deliver 158 to 165 target, which is capped by higher-for-longer rate regime

→ vs aggressive: Conflating 2.17 percent dividend income with downside protection; yield does not offset a 7 percent drawdown

→ vs conservative: Treating one session as definitive top is overreach; one session also doesn't make a confirmed breakout

→ vs conservative: Implying 10 to 15 percent drawdown is the base case overshoots the risk magnitude in the bearish direction

→ vs conservative: 15 to 25 percent trim into a single supply zone is a directional bet disguised as risk management; if wrong about breakout failure, must chase back in at higher prices with less capital

→ vs conservative: Applying the unfavorable risk-reward math as if it forecloses all adding forever is too rigid; the math improves at pullback zones